Boston Scientific Stent Approved in France
Posted on: Wednesday, 15 February 2006, 12:01 CST
Boston Scientific said Wednesday the French government approved for reimbursement its Taxus Liberte stent system.
The approval means the Taxus Liberte paclitaxel-eluting coronary stent system will be available to coronary artery disease patients in private and public hospitals throughout France.
Until now, many French patients suffering from coronary artery disease were unable to benefit from the Taxus Liberte stent system due to the lack of reimbursement, Philippe Brunel, interventional cardiologist at the Nouvelles Cliniques Nantaises in Nantes, said in a statement released by Boston Scientific.
The Taxus Liberte stent system offers cardiologists and patients benefits due to its superior deliverability, Brunel added.
More than 165,000 stents are implanted annually in France, with about half of these being drug-eluting stents such as the Taxus Liberte system.
Market analysts predict that Boston Scientific will beat rival Medtronic to the U.S. drug-eluting coronary stent market in 2006.
Medtronic makes the Endeavor stent, which the company launched in foreign markets last year.
Source: United Press International
Related Articles
- FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent
- FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
- SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
- Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent
- Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
- Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
- Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
- TAXUS(R) Liberte(TM) Drug-Eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
- First Patient Enrolled in SONOMA Post-Market Approval Study of Boston Scientific NexStent(R) Carotid Stent System and FilterWire EZ(TM) Embolic Protection Device
- Boston Scientific Expects Results at Upcoming World Congress of Cardiology to Reinforce Safety & Efficacy Record of TAXUS(R) Drug-Eluting Stent Systems
 |
 |
User Comments (0)
RSS Feeds